XNCR (Xencor) Institutional Ownership : 111.71% (As of Jul. 11, 2025)

View and export this data going back to 2013. Start your Free Trial

What is Xencor Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Xencor's institutional ownership is 111.71%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Xencor's Insider Ownership is 11.99%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Xencor's Float Percentage Of Total Shares Outstanding is 69.97%.

Xencor Institutional Ownership Historical Data

The historical data trend for Xencor's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xencor Institutional Ownership Chart

Xencor Historical Data

The historical data trend for Xencor can be seen below:

	2024-09-30	2024-10-31	2024-11-30	2024-12-31	2025-01-31	2025-02-28	2025-03-31	2025-04-30	2025-05-31	2025-06-30
Institutional Ownership	63.06	63.69	64.39	68.11	67.00	66.18	65.69	65.05	64.84	64.50

Xencor Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Xencor Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xencor Inc (NAS:XNCR) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

XE9:Germany

Address

465 North Halstead Street, Suite 200, Pasadena, CA, USA, 91107

Website

https://www.xencor.com

Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.

Executives

Nancy Valente	director	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Celia Eckert	officer: VP, GENERAL COUNSEL	C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
John R Desjarlais	officer: SR. VICE PRESIDENT & CSO	C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Bassil I Dahiyat	director, officer: PRESIDENT & CEO	C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Alan Bruce Montgomery	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Richard J Ranieri	director	3005 FIRST AVE, SEATTLE WA 98121
Ellen Feigal	director	C/O XENCOR INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Dagmar Rosa-bjorkeson	director	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Kevin Charles Gorman	director	12790 EL CAMINO REAL, SAN DIEGO CA 92130
Kurt A Gustafson	director	11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
John J Kuch	officer: SR. VICE PRESIDENT & CFO	C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Barbara Klencke	director	C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DRIVE, SUITE 110, SAN MATEO CA 94404
Allen Yang	officer: SR. VICE PRESIDENT & CMO	C/O XENCOR INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Yujiro S Hata	director	C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Stafford John S Iii	10 percent owner	230 SOUTH LASALLE STREET 400, CHICAGO IL 60604